ADMA Biologics (NASDAQ:ADMA) Upgraded at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other brokerages have also recently weighed in on ADMA. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $32.00.

ADMA Biologics Stock Down 1.2%

NASDAQ ADMA opened at $16.38 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics has a 52 week low of $13.50 and a 52 week high of $25.67. The stock has a market capitalization of $3.90 billion, a P/E ratio of 27.30 and a beta of 0.51. The stock has a fifty day moving average of $17.13 and a 200-day moving average of $16.80.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the previous year, the company posted $0.46 EPS. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. On average, equities research analysts forecast that ADMA Biologics will post 0.51 EPS for the current year.

Institutional Trading of ADMA Biologics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Salomon & Ludwin LLC bought a new position in ADMA Biologics during the third quarter worth $25,000. Rothschild Investment LLC boosted its holdings in shares of ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,495 shares during the period. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics during the 4th quarter worth about $29,000. Clearstead Advisors LLC grew its stake in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 795 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in ADMA Biologics in the 3rd quarter valued at about $34,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.